Effect of Intravenous Iron Dextran on Kidney Outcomes in Acute Kidney Injury with Iron Deficiency

Kidney360 2026 Open access

Read full text
Authors: Jonathan S. Chávez-Iñiguez, Miguel Ibarra-Estrada, Edgar Joel Carmona-Morales, Ana Ron-Magaña, Rolando Claure-Del Granado, Juan Carlos Velez, Gael Chávez-Alonso, Carlos E. Orozco-Chan, Estefania Villalvazo-Maciel, Tania M. Anaya-Arce, Gonzálo Rodríguez-García, Guillermo Navarro-Blackaller
+6 more Ramón Medina-González, Alejandro Martínez Gallardo-González, Luz Alcantar-Vallin, Juan A. Gómez-Fregoso, Gabriela J. Abundis-Mora, Guillermo García-García
DOI: 10.34067/kid.0000001136
Cited by: 2
References: 41

Abstract

KEY POINTS: Iron deficiency is common in patients with AKI. It is unknown whether treating iron deficiency in AKI with intravenous iron reduces the risk of major adverse kidney events. In AKI and iron deficiency, intravenous iron did not reduce the risk of major adverse kidney events at 90 days. BACKGROUND: During AKI, iron deficiency may contribute to worse clinical outcome by interfering cellular repair. Correcting iron deficiency with intravenous (IV) dextran iron may reduce the risk of major adverse kidney events (MAKEs). We aimed to assess whether IV iron was more efficacious than conventional management for reducing MAKE in patients with AKI-iron deficiency. METHODS: In a phase 2 randomized controlled trial, from July 2022 to September 2024, patients with AKI and iron deficiency (iron levels

Fields of Study & Subjects

Acute Kidney Injury Research Erythropoietin and Anemia Treatment Chronic Kidney Disease and Diabetes

Publication details

Journal / source
Kidney360
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
7
Issue
7
Pages
1545–1555
Publication date
27 January 2026
Language
EN